TNET Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
TNET is NOT a good buy right now for an impatient investor. Despite today’s strong +4.76% regular-session pop and notable hedge-fund buying, the technical trend is still bearish (stacked moving averages) and recent fundamentals are weakening (Q3 2025 YoY declines in revenue, EPS, and net income). With earnings coming up on 2026-02-16 (pre-market) and no supportive near-term news catalysts, the risk/reward for buying immediately at ~61.24 looks unfavorable.
Intellectia Proprietary Trading Signals
Trend and momentum lean bearish overall. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), implying the stock remains in a broader downtrend/rally-within-downtrend structure. MACD histogram is negative (-0.402) and still below zero (bearish momentum), though it is “negatively contracting,” which can indicate downside pressure is easing rather than accelerating. RSI(6) at ~52 is neutral (no clear oversold bounce signal).
Key levels: price ~61.24 is just above the pivot (60.966). Near-term resistance sits at R1 ~63.724 (then R2 ~65.428). Supports are S1 ~58.208 and S2 ~56.504. Given the bearish MA stack, rallies into 63.7–65.4 are more likely to face supply unless momentum improves materially. Pattern-based stats provided also lean muted/soft near-term (next day slightly negative, next week flat, next month modestly positive).
and improve momentum, it could shift from “bearish trend rally” toward a more constructive setup.
and MACD remains below zero, increasing the odds that the recent pop fades.
showed declines across key lines (revenue, EPS, net income, gross margin), which pressures valuation support.
Latest quarter provided: 2025/Q3. • Revenue: $1.232B, -1.60% YoY (top-line contraction). • Net income: $34M, -24.44% YoY (profitability weakening faster than revenue). • EPS: $0.71, -21.11% YoY (earnings pressure). • Gross margin: 16.23%, down ~3.22% YoY (margin compression). Overall, the quarter shows decelerating/negative growth and margin pressure—fundamentals currently do not support an “impatient buy-the-rip” approach.
Recent Street tone is cautious/neutral. • 2026-01-08: TD Cowen trimmed PT to $64 from $65; rating Hold. • 2025-12-05: Truist initiated Hold with $62 PT, citing macro uncertainty and medical utilization headwinds, while expecting eventual repricing and potential channel/labor initiatives to help (timing uncertain).
Wall Street pros: acknowledges levers to improve margins/growth (repricing, indirect channel, offshoring) and potential stabilization. Wall Street cons: near-term macro/benefit cost headwinds and uncertain timing; Hold ratings and PTs clustered around ~$62–$64 suggest limited upside from ~61.24 without clearer execution/momentum.
